[go: up one dir, main page]

MX2019004347A - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. - Google Patents

Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.

Info

Publication number
MX2019004347A
MX2019004347A MX2019004347A MX2019004347A MX2019004347A MX 2019004347 A MX2019004347 A MX 2019004347A MX 2019004347 A MX2019004347 A MX 2019004347A MX 2019004347 A MX2019004347 A MX 2019004347A MX 2019004347 A MX2019004347 A MX 2019004347A
Authority
MX
Mexico
Prior art keywords
compounds
pyrimidin
amine
pirazol
same
Prior art date
Application number
MX2019004347A
Other languages
English (en)
Other versions
MX381873B (es
Inventor
Müller Thomas
Lindner Niels
Klar Jürgen
Gromov Alexey
Schmeck Carsten
Giese Anja
Collins Karl
Ehrmann Alexander
Willwacher Jens
Engel David
Philippe Dieskau Andre
Kahnert Antje
Lena Andreevski Anna
Dreher Jan
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2019004347A publication Critical patent/MX2019004347A/es
Publication of MX381873B publication Critical patent/MX381873B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos sustituidos de 6-(1H-pirazol-1-iI)pirimidin-4-amina de la fórmula general (I) tal como se describen y definen en el presente, procedimientos para preparar dichos compuestos, compuestos de productos intermedios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de enfermedades cardiovasculares y renales,como agente único o en combinación con otros compuestos activos.
MX2019004347A 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. MX381873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193953 2016-10-14
PCT/EP2017/075630 WO2018069222A1 (en) 2016-10-14 2017-10-09 Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
MX2019004347A true MX2019004347A (es) 2019-07-01
MX381873B MX381873B (es) 2025-03-13

Family

ID=57136772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004347A MX381873B (es) 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.

Country Status (28)

Country Link
US (2) US11208400B2 (es)
EP (1) EP3526212B1 (es)
JP (1) JP2019532961A (es)
KR (1) KR20190065402A (es)
CN (1) CN110191884A (es)
AR (1) AR109947A1 (es)
AU (1) AU2017341324A1 (es)
BR (1) BR112019007496A2 (es)
CA (1) CA3040166A1 (es)
CL (1) CL2019001004A1 (es)
CO (1) CO2019003761A2 (es)
CR (1) CR20190192A (es)
CU (1) CU24518B1 (es)
DO (1) DOP2019000099A (es)
EA (1) EA201990947A1 (es)
EC (1) ECSP19026563A (es)
GE (2) GEP20217269B (es)
IL (1) IL265923A (es)
JO (1) JOP20190080A1 (es)
MA (1) MA46514A (es)
MX (1) MX381873B (es)
PE (1) PE20191549A1 (es)
PH (1) PH12019500808A1 (es)
SG (1) SG11201903305XA (es)
TN (1) TN2019000114A1 (es)
TW (1) TW201825477A (es)
UY (1) UY37444A (es)
WO (1) WO2018069222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN115403524A (zh) * 2021-05-26 2022-11-29 浙江省化工研究院有限公司 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法
CA3267500A1 (en) 2022-09-19 2024-03-28 Basf Se AZOLE PESTICIDE COMPOUNDS

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
WO2000043402A2 (en) 1999-01-21 2000-07-27 Board Of Regents, The University Of Texas System Inhibitors of intestinal apical membrane na/phosphate co-transportation
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20080269193A1 (en) * 2007-04-16 2008-10-30 Kenneth He Huang Tetrahydroindole and Tetrahydroindazole Derivatives
JP2008296610A (ja) 2007-05-29 2008-12-11 Toyota Motor Corp 車両用動力伝達装置の制御装置
CA2720888A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX342521B (es) 2011-10-27 2016-10-03 Astellas Pharma Inc Derivado de n-tienilbenzamida sustituido con aminoalquilo.
WO2013082756A1 (en) 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
WO2014152716A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JO3336B1 (ar) * 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
WO2016071212A1 (en) 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CN105631664A (zh) 2014-11-26 2016-06-01 华为终端（东莞）有限公司 一种非接触支付方法、装置及系统
CN107406442B (zh) * 2014-12-23 2021-08-17 达纳－法伯癌症研究所公司 作为egfr抑制剂的新的嘧啶和治疗病症的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019004345A (es) 2016-10-14 2019-07-01 Novartis Ag Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida.
WO2018069907A1 (en) 2016-10-14 2018-04-19 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Also Published As

Publication number Publication date
TW201825477A (zh) 2018-07-16
CL2019001004A1 (es) 2019-08-30
MX381873B (es) 2025-03-13
PH12019500808A1 (en) 2020-01-20
CN110191884A (zh) 2019-08-30
GEP20217269B (en) 2021-06-25
AR109947A1 (es) 2019-02-06
BR112019007496A2 (pt) 2019-09-10
CU20190035A7 (es) 2019-11-04
EP3526212A1 (en) 2019-08-21
GEAP202115076A (en) 2021-01-25
UY37444A (es) 2018-05-31
ECSP19026563A (es) 2019-04-30
CR20190192A (es) 2019-09-02
DOP2019000099A (es) 2019-07-15
US11208400B2 (en) 2021-12-28
AU2017341324A1 (en) 2019-05-02
CO2019003761A2 (es) 2019-04-30
JP2019532961A (ja) 2019-11-14
SG11201903305XA (en) 2019-05-30
EA201990947A1 (ru) 2019-08-30
TN2019000114A1 (en) 2020-10-05
PE20191549A1 (es) 2019-10-24
IL265923A (en) 2019-06-30
WO2018069222A1 (en) 2018-04-19
JOP20190080A1 (ar) 2019-04-11
CU24518B1 (es) 2021-06-08
MA46514A (fr) 2019-08-21
US20230065629A1 (en) 2023-03-02
KR20190065402A (ko) 2019-06-11
EP3526212B1 (en) 2021-12-22
CA3040166A1 (en) 2018-04-19
US20200055842A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2017002650A1 (es) Compuestos novedosos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
JO3447B1 (ar) 2-(مورفولين-4-يل)-7،1-نفثيريدينات
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
ECSP14013231A (es) Imidazopiridazinas sustituidas con amino
PE20151759A1 (es) Imidazopiridazinas sustituidas
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201600006A (es) Pirazolo-piridinaminas sustituidas
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
ECSP19026563A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino
BR112017009852A2 (pt) composto, composição, e, usos de um composto